Clinical Trials Logo

Adverse Event clinical trials

View clinical trials related to Adverse Event.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04716075 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

ACALLO
Start date: August 19, 2019
Phase: Phase 2
Study type: Interventional

In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib will be used before alloSCT with the intention to reduce tumor burden and after transplant to augment disease control.

NCT ID: NCT04018898 Active, not recruiting - Hospitalization Clinical Trials

Older Emergency Department Users and Short-term Adverse Events at the Index Visit

Start date: July 23, 2019
Phase:
Study type: Observational

This study evaluates the difference between PRISMA-7 and ER2 tool. There are some differences between PRISMA-7 and ER2 tool. The differences consist in evaluation criteria that are used to perform the both surveys. We suppose that evaluation criteria of PRISMA-7 is not accurately enough to calculate the length of hospital stay and to predict the short-term outcomes.